XML 15 R3.htm IDEA: XBRL DOCUMENT v3.4.0.3
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
 3 Months Ended
Mar. 31, 2016
Mar. 31, 2015
Revenues:    
Revenue under collaborative research and development arrangements $ 1,796,857 $ 4,245,571
Revenue under collaborative research and development arrangements with affiliated entity 137,000 112,500
Grants and miscellaneous revenue 6,176,298 808,566
Total revenues 8,110,155 5,166,637
Operating expenses:    
Research and development 18,189,160 9,426,320
General and administrative 5,371,613 4,107,928
Total operating expenses 23,560,773 13,534,248
Loss from operations (15,450,618) (8,367,611)
Other income (expense):    
Interest and other income, net 333,070 138,276
Change in fair value of common stock warrants, net (406,249) (1,227)
Gain (loss) on investment in affiliated entity 7,480,977 (2,352,309)
Net loss (8,042,820) (10,582,871)
Net loss attributable to non-controlling interest 0 1,092
Net loss attributable to Inovio Pharmaceuticals, Inc. $ (8,042,820) $ (10,581,779)
Net loss per common share attributable to Inovio Pharmaceuticals, Inc. stockholders:    
Basic (in USD per share) $ (0.11) $ (0.17)
Diluted (in USD per share) $ (0.11) $ (0.18)
Weighted average number of common shares outstanding used in per share calculations:    
Basic (in shares) 72,230,411 60,741,082
Diluted (in shares) 72,230,411 60,913,423